Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Casey Liveringhouse, Kujtim Latifi, Amalin G. Asous, Nghi B. Lam, Stephen A. Rosenberg, Thomas J. Dilling, Gretchen V. MacMillan, Alberto Chiappori, Eric B. Haura, Ben Creelan, Jhanelle E. Gray, Tawee Tanvetyanon, Michael Shafique, Andreas Saltos, Ashley Weiner, Jeffrey Clarke, Chris R. Kelsey, Sungjune Kim, J.J. Caudell, Trevor Rose, José R. Conejo-García, Jiannong Li, Michael J. Schell, Scott Antonia, Bradford A. Perez
Topics & Concepts
MedicinePulmonary toxicityCommon Terminology Criteria for Adverse EventsInternal medicinePneumonitisNivolumabIpilimumabLung cancerAdverse effectPhases of clinical researchGastroenterologySurgeryChemotherapyToxicityCancerLungImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations